Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study

Annals of Oncology

Volumn 30, Issue 3, 2019, Pages 397-404

  Adams, S ^a   Schmid, P ^b   Rugo, H S ^c   Winer, E P ^d   Loirat, D ^e   Awada, A ^f   Cescon, D W ^g   Iwata, H ^h   Campone, M ⁱ   Nanda, R ^j   Hui, R ^k   Curigliano, G ^l,m   Toppmeyer, D ⁿ   O'Shaughnessy, J ^o,p,q   Loi, S ^r   Paluch Shimon, S ^s   Tan, A R ^t   Card, D ^u   Zhao, J ^u   Karantza, V ^u   Cortes J ^v,w,x   more..

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e INSTITUT CURIE   (France)

^f JULES BORDET INSTITUTE   (Belgium)

^g UNIVERSITY OF TORONTO   (Canada)

^h AICHI CANCER CENTER HOSPITAL   (Japan)

ⁱ UMR INSERM U892 CNRS 6299   (France)

^j UNIVERSITY OF CHICAGO   (United States)

^k UNIVERSITY OF SYDNEY   (Australia)

^l UNIVERSITY OF MILAN   (Italy)

^m EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁿ RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^o BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^p TEXAS ONCOLOGY   (United States)

^q US Oncology   (United States)

^r PETER MACCALLUM CANCER CENTRE   (Australia)

^s SHEBA MEDICAL CENTER   (Israel)

^t LEVINE CANCER INSTITUTE   (United States)

^u MERCK RESEARCH LABORATORIES   (United States)

^v VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^w HOSPITAL RAMÓN Y CAJAL   (Spain)

^x Universidad Europea de Madrid Centro Nacional de Investigaciones Cardiovasculares Carlos III   (Spain)

more..

Author keywords

anti PD 1; immunotherapy; pembrolizumab; triple negative breast neoplasms

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TAXANE DERIVATIVE; BRIDGED COMPOUND; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TAXANE; TAXOID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; COLITIS; DECREASED APPETITE; DIABETES MELLITUS; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFUSION RELATED REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METASTATIC BREAST CANCER; MONOTHERAPY; MYOCARDITIS; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; CLINICAL TRIAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; BRIDGED-RING COMPOUNDS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGRESSION-FREE SURVIVAL; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85058928617     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy517     Document Type: Article

References (20)

1. Miles DW, Dieras V, Cortes J et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013; 24(11): 2773-2780.
2. Yardley DA, Coleman R, Conte P et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol 2018; 29(8): 1763-1770.
3. Robson M, Im SA, Senkus E et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377(6): 523-533.
4. Litton JK, Rugo HS, Ettl J et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018; 379(8): 753-763.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252-264.
6. Mittendorf EA, Philips AV, Meric-Bernstam F et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014; 2(4): 361-370.
7. Schalper KA, Velcheti V, Carvajal D et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014; 20(10): 2773-2782.
8. Ali HR, Glont SE, Blows FM et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol 2015; 26(7): 1488-1493.
9. Nanda R, Chow LQ, Dees EC et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016; 34(21): 2460-2467.
10. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. JCO 2010; 28(16): 2784-2795.
11. Senkus E, Cardoso F, Pagani O. Time for more optimism in metastatic breast cancer? Cancer Treat Rev 2014; 40(2): 220-228.
12. Adams S, Loi S, Toppmeyer D et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 2019; 30(3): 405-411.
13. Tumeh PC, Hellmann MD, Hamid O et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 2017; 5(5): 417-424.
14. Dirix LY, Takacs I, Jerusalem G et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat 2018; 167(3): 671-686.
15. Emens LA, Cruz C, Eder JP et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer. A phase 1 study. JAMA Oncol 2018 September 13 [epub ahead of print], doi:10.1001/jamaoncol.2018.4224.
16. Tolaney S, Savulsky C, Aktan G et al. Abstract P5-15-02: phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Cancer Res 2017; 77(Suppl 4): Abstract P5-15-02-P5-15-02.
17. Schmid P, Adams S, Rugo HS et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379: 2108-2121.
18. Santa-Maria CA, Kato T, Park JH et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget 2018; 9: 18985-18996.
19. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14(4): 847-856.
20. Loi S, Adams S, Schmid P et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. Ann Oncol 2017; 28: doi:10.1093/annonc/mdx440.005.